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INTRODUCTION
               Dyspepsia is a nonspecific term to denote upper abdominal discomfort that is thought to arise 
from the upper-GI tract.1,2 Dyspepsia may encompass a variety of more specific symptoms, including 
epigastric discomfort,bloating, anorexia, early satiety, belching or regurgitation, nausea, and heartburn. 
               Symptoms of dyspepsia most commonly result from 1 of 4 underlying disorders: peptic ulcer  
disease, GERD, functional disorders (nonulcer dyspepsia),and malignancy: malignancy is present in 
1% to 3% of patients with dyspepsia  and peptic ulcer disease in another 5% to 15%.3-6
                The estimated annual prevalence in western countries is approximately 25% to 40% 
accounting  2-5% of all primary care consultations.7  In India  almost one-third of the population has 
symptoms.8 
                Endoscopy is the procedure of choice for the diagnostic evaluation of this common, 
longterm, symptom shifting, expensive disorder.It offers the potential for early diagnosis of structural 
disease.Yet,  given  the  large  numbers  of  patients  with  dyspepsia,  it  is  not  practical  to  perform 
endoscopy in all patients with dyspepsia.
                  Age and alarm features have been used in an attempt to identify those patients with 
dyspepsia who harbor structural disease. 
                 Patients with a new onset of dyspepsia after 45 to 55 years of age and those with symptoms 
or  signs  (unintended  weight  loss,  Upper  Gastrointestinal  bleeding  or  iron  deficiency  anemia, 
progressive dysphagia, persistent vomiting, palpable mass, lymphadenopathy,  jaundice) that suggest 
structural disease are advised to undergo initial endoscopy.3
                          Patients with alarm features and dyspepsia have significantly worse outcomes than the 
population at large.
                 In a prospective questionnaire study, patients with alarm symptoms and dyspepsia had a 
significant increase in both GI cancer and mortality over a 3-year period.9Even though alarm features 
predict relatively poor patient outcomes, they have a low predictive value for GI cancer.
                  In a meta-analysis of 15 studies that evaluated more than 57,000 patients with dyspepsia, 
alarm symptoms showed a positive predictive value for GI cancer 
of <11% in all but 1 of these studies.5 The negative predictive value of alarm symptoms was much 
higher, at > 97%, because of the low prevalence of GI cancer in that population.
                   A second meta-analysis of 26 studies that totaled more than 16,000 patients with dyspepsia  
showed similar results: the positive predictive value of alarm symptoms for upper-GI cancer was only 
5.9% and the negative predictive value 
was >99%.6
                         Unfortunately, clinical impression, demographics,risk factors, history items, and 
symptoms also do not adequately distinguish structural disease from functional disease in patients with 
dyspepsia  who  are  referred  for  endoscopy.10 It  is  worth  noting  that  one  fourth  of  patients  with 
malignancy and dyspepsia have no alarm symptoms.6
AIM OF THE STUDY
1.To determine the predictive factors of gastroesophageal malignancy   in    
       dyspeptic  patients presenting with alarm features.
2.To arrive at or to refine indications for Upper Gastrointestinal Endoscopy in patients with 
dyspepsia. 
                                  REVIEW OF LITERATURE
DEFINITIONS
Dyspepsia  is  defined  as  chronic  or  recurrent  pain  or  discomfort  centered  in  the  upper  
abdomen. Discomfort is defined as a subjective negative feeling that is nonpainful, and can 
incorporate  a  variety  of  symptoms  including  early  satiety  or  upper  abdominal  fullness.  
Patients presenting with predominant or frequent (more than once a week) heartburn or acid  
regurgitation should be considered to have gastroesophageal  reflux disease (GERD) until  
proven otherwise – ACG 2005.11
NICE Guidelines (2004)12
Dyspepsia in unselected patients in primary care is defined broadly to include patients with recurrent 
epigastric pain, heartburn or acid regurgitation with or without bloating, nausea or vomiting.
The broad definition of dyspepsia has complicated research efforts and limited the value of research 
observations  to  clinical  practice.  In  response,  some  investigators  have  attempted  to  clarify  the 
definition of dyspepsia by using defined criteria, for example ROME criteria.
The Rome committees serve as the nidus to modify and update information on these disorders for 
research and patient  care.  By necessity,  the group develops criteria  by consensus (via the “Delphi 
Approach”) and the process has matured through three generations, producing a series of publications 
(Rome I, II and III), with an increased evidence-based approach to the recommendations.
ROME III(2006) criteria13 defines dyspepsia in functional gastroduodenal disorders. 
Functional Gastroduodenal Disorders are classified into 
B. Functional gastroduodenal disorders
  B1. Functional dyspepsia
     B1a. Postprandial distress syndrome
     B1b. Epigastric pain syndrome
  B2. Belching disorders
     B2a. Aerophagia
     B2b. Unspecified excessive belching
  B3. Nausea and vomiting disorders
     B3a. Chronic idiopathic nausea
     B3b. Functional vomiting
     B3c. Cyclic vomiting syndrome
B4. Rumination syndrome in adults
B1. Diagnostic Criteria* for Functional Dyspepsia
1. One or more of:
   a. Bothersome postprandial fullness
   b. Early satiation
   c. Epigastric pain
   d. Epigastric burning
AND
2. No evidence of structural disease (including at upper endoscopy) that is likely to 
explain the symptoms.
*Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis
B1a. Diagnostic Criteria* for Postprandial Distress Syndrome
Must include one or both of the following:
1. Bothersome postprandial fullness, occurring after ordinary sized meals, at least 
several times per week.
2. Early satiation that prevents finishing a regular meal, at least several times per 
week.
*Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis
Supportive criteria
1. Upper abdominal bloating or postprandial nausea or excessive belching can be 
present
2. EPS may coexist
1b. Diagnostic Criteria* for Epigastric Pain Syndrome
Must include all of the following:
1. Pain or burning localized to the epigastrium of at least moderate severity at least 
once per week.
2. The pain is intermittent.
3. Not generalized or localized to other abdominal or chest regions.
4. Not relieved by defecation or passage of flatus.
5. Not fulfilling criteria for gallbladder and sphincter of Oddi disorders.
*Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis.
Supportive criteria
1. The pain may be of a burning quality but without a retrosternal component.
2. The pain is commonly induced or relieved by ingestion of a meal but may occur 
while  Fasting.
3. Postprandial distress syndrome may coexist.
The ROME committee proposed to define Functional dyspepsia at 2 levels. 
A general, more umbrella definition of Functional dyspepsia , to be used mainly for clinical purposes, 
and although further research on more specific definitions is ongoing, is provided under category B1. 
However, particularly for pathophysiological and therapeutic research purposes, newly defined entities 
of 
(1) meal-induced dyspeptic symptoms (PDS, defined under category B1a)
                                                and 
(2) epigastric pain (EPS, defined under category B1b),  used operatively.
DYSPEPTIC SYMPTOMS AND THEIR DEFINITIONS: 
Epigastric pain 
Epigastric refers to the region between the umbilicus and lower end of the sternum, and marked by the 
midclavicular lines.  Pain refers to a subjective,  unpleasant sensation;  some patients  may feel  that 
tissue damage is occurring. Other symptoms may be extremely bothersome without being interpreted 
by the patient as pain.
Epigastric burning 
Epigastric refers to the region between the umbilicus and lower end of the sternum, and marked by the 
midclavicular lines. Burning refers to an unpleasant subjective sensation of heat.
Postprandial fullness 
An unpleasant sensation like the prolonged persistence of food in the stomach.
Early satiation 
A feeling that the stomach is overfilled soon after starting to eat, out of proportion to the size of the 
meal being eaten, so that the meal cannot be finished. Previously, the term “early satiety” was used,  
but  satiation  is  the  correct  term  for  the  disappearance  of  the  sensation  of  appetite  during  food 
ingestion.
Uninvestigated versus investigated dyspepsia
It is important to distinguish the subjects with dyspeptic symptoms who have not been investigated 
from  patients  with  a  diagnostic  label  after  investigation,  with  or  without  an  identified  causal 
abnormality.
Organic versus idiopathic dyspepsia
From an  etiological  viewpoint,  patients  with  dyspeptic  symptoms  can  be  subdivided  into  2  main 
categories:
1. Those with an identified organic or metabolic cause for the symptoms where, if the disease improves 
or is eliminated, symptoms also improve or resolve (eg, peptic ulcer disease, GERD with or without 
esophagitis, malignancy, pancreaticobiliary disease, or medication use).
2. Those with no identifiable explanation for the symptoms.In some of these patients, an identifiable 
pathophysiological  or  microbiologic  abnormality  of  uncertain  clinical  relevance  (eg,  Helicobacter  
pylori gastritis) may be present, which is not thought to explain the symptoms. Others have abnormal 
motor or sensory dysfunction 
(eg,  altered  gastric  emptying,  fundic  dysaccommodation,  or  gastroduodenal  hypersensitivity)  of 
uncertain  significance.  This broad group of patients  with idiopathic dyspepsia  has previously been 
referred to as nonulcer dyspepsia, essential dyspepsia, idiopathic dyspepsia, or functional dyspepsia.
EPIDEMIOLOGY
Approximately 20% to 30% of people in the community each year report chronic or recurrent dyspeptic 
symptoms.14,15 Although  these  data  represent  uninvestigated  dyspepsia  and  often  also  included 
heartburn, an organic cause is found in only a minority of dyspeptic subjects who are investigated, and 
hence it is reasonable to assume that the majority would have functional dyspepsia.16,17
Based  on  prospective  studies  of  subjects  who  report  dyspeptic  symptoms  for  the  first  time,  the 
incidence  is  approximately  1%  per  year.18 The  majority  of  patients  with  unexplained  dyspeptic 
symptoms  continue  to  be  symptomatic  over  the  long-term  despite  periods  of  remission.19 
Approximately, 1 in 2 subjects is estimated to seek health care for their dyspeptic symptoms at some 
time in their life.20 Pain severity and anxiety (including fear of serious disease) appear to be factors 
associated with consulting behavior.20,21
HETEROGENEITY OF FUNCTIONAL  SYMPTOMS: SUBGROUPS
It seems likely that chronic unexplained dyspepsia includes different types of patients with distinct 
underlying pathophysiologies who require different management approaches.22  However, it has been 
particularly difficult to identify these subgroups reliably. Subclasses based on symptom clusters have 
been  proposed. In  clinical  practice,  however,  this  classification  showed  great  overlap  between 
subclasses,  limiting  its  value. Identifying  the  predominant  symptom  was  shown  to  distinguish 
subgroups  with  different  demographic  and  symptomatic  properties  and  with  some  relationship  to 
putative  pathophysiological  mechanisms  like delayed gastric  emptying and presence  of  H pylori.23 
Thus, the Rome II committee proposed a subdivision according to the predominant symptom being 
pain or discomfort, but this subdivision
has also been criticized because of the difficulty distinguishing pain from discomfort, the lack of an 
accepted  definition  of  the  term  predominant,  number  of  patients  who  do  not  fit  into  one  of  the 
subgroups, and especially the lack of stability, even over short time periods.24,25 
A  different  approach  was  based  on  attempts  to  identify  pathophysiology-based  subgroups.  Thus, 
associations were shown between symptom patterns and delayed gastricemptying,26,27  impaired fundic 
accommodation,28 and visceral hypersensitivity.29 However, the association of these pathophysiological 
mechanisms with symptoms has not been confirmed in other studies.30-32
PATHOPHYSIOLOGICAL DISTURBANCES IN FUNCTIONAL DYSPEPSIA
Approximately 40% of patients with functional dyspepsia have delayed gastric emptying31. Stanghellini 
et al. in 343 Italian patients reported that delayed gastric emptying was significantly more frequent in 
patients characterized by female sex, low body weight, presence of relevant and severe postprandial 
fullness,  nausea,vomiting,  and  absence  of  severe  epigastric  pain;  female  sex,relevant  and  severe 
postprandial  fullness,  and  severe  vomiting  were  independently  associated  with  delayed  gastric 
emptying of solids.34
                In a separate study of 483 patients, the same Italian group identified distinct subgroups based 
on predominant  symptoms and gastric  emptying;  one was characterized by predominant  epigastric 
pain, male gender and normal gastric emptying, and a second by predominant nonpainful symptoms, 
female  gender,  and  a  high  frequency  of  associated  irritable  bowel  syndrome  and  delayed  gastric 
emptying.23 
                  Sarnelli et al. also reported that delayed gastric emptying was associated with postprandial 
fullness and vomiting.27 Other studies, however,  have failed to identify a definite symptom profile 
associated with delayed gastric emptying suggesting there is not a simple association.
                   There is evidence that the stomach and other regions of the gut including the duodenum and 
esophagus are  hypersensitive  to  distention in  functional  dyspepsia,  although this  applies  only in  a 
subgroup35-38. 
Tack  et  al.  recently  reported  in  160 patients  with  functional  dyspepsia  that  one  third  had  gastric 
hypersensitivity  and  this  abnormality  was  associated  with  increased  postprandial  pain  as  well  as 
belching and weight loss.29
                      In a barostat study, Tack et al.  studied patients with functional dyspepsia; impaired 
gastric  accommodation  to  a  meal  (a  “stiff  fundus”)  was  found in  40%,  and this  abnormality  was 
associated  with  early  satiety  and  weight  loss  but  not  with  hypersensitivity  to  gastric  distention, 
presence of  H. pylori, or delayed gastric emptying.29However, Boeckxstaens  et al.  failed to replicate 
these  findings;  while  postprandial  symptoms  were  more  often  evoked  with  a  meal  in  functional 
dyspepsia, there was no clear symptom profile that was associated with a failure of fundic relaxation.30
                        Noninvasive testing is available to assess abnormal fundic accommodation including 
gastric ultrasound, SPECT, and MRI, but the clinical relevance of identifying this abnormality remains 
in some dispute in terms of defining therapeutic interventions.39
                       New clinical tests of gastric function are under evaluation. The water-load test and 
nutrient-load test may help identify gastric dysfunction in clinical practice. Currently, patients with 
gastroduodenal  motility  disturbances,gastroduodenal  hypersensitivity,  or  other  pathophysiological 
abnormalities of uncertain relevance are not excluded from the functional dyspepsia umbrella.
ALARM FEATURES AND IDENTIFICATION OF STRUCTURAL
DISEASE IN UNINVESTIGATED DYSPEPSIA
New-onset dyspepsia in older age is an alarm feature or redflag. The American College of Physicians 
in  1985 published a  guideline recommending that  patients  who were over the age of 45 deserved 
referral for prompt endoscopy to rule out underlying malignancy, as gastric cancer is very rare in the 
United States below the age of 45 yr although it increases thereafter. 
Some studies have reported that older  age is  an independent  risk factor  for identifying underlying 
structural abnormalities, but the results have been inconsistent.40,41   
 Recent ACG guidelines recommends prompt endoscopy for patients over the age 
of 55 without alarm features.11 
The recommended age threshold for endoscopy also differs among different regions in Asia.42,43
                     In Hong Kong, 10% of patients with gastric cancer are aged less than 
45 years. Sung et al reported that gastric cancer was found in three patients (0.1%), who were aged 
below 45 years and who did not have alarm symptoms, among 2,918 patients with dyspepsia. The 
investigators suggested that the “test-and-endoscope” strategy might be a more feasible approach for 
dyspepsia in Hong Kong.42
                    In Singapore, the relative frequency of gastric cancer was 1.15 per 1,000 upper 
endoscopies in patients with simple dyspepsia and aged below 45 years. An age threshold of 45 years 
was therefore recommended for patients withsimple dyspepsia in Singapore.43
                     A study from Taiwan considered that 40 years of age might be an appropriate age 
threshold for endoscopy, as 2.4 cases would be missed every year if they followed the international 
guidelines of 45 years.44
                    A recent prospective study in Southern India has arrived cut-off age for malignancy which 
was between 35 and 44 years ( for females 38 years with sensitivity of 70%,specificity of 61and  for 
males, 43.5 years with sensitivity of 88%, specificity of 62%).45
Several other alarm features have been traditionally applied to try and identify serious underlying 
disease in dyspepsia,especially malignancy. 
These include
1.unexplained weight loss
2.anorexia 
8.anemia
9.jaundice 
3.Early satiety 
4.vomiting
5.progressive dysphagia
6.odynophagia 
7.bleeding
10.an abdominal mass 
11.lymphadenopathy
12.family history of upper gastrointestinal 
tract cancer 
13.history of peptic ulcer
14.previous gastric surgery or malignancy 
Upper gastrointestinal malignancy is rarely present in young patients without alarm features, but the 
positive predictive value of alarm features remains very poor.46,47 Many studies and meta-analysis gives 
variable outcomes in patients with alarm features.
                                  Kapoor et al determined the predictive value of alarm symptoms in a cohort of 
1,852 patients  undergoing upper  endoscopy.  The mean age for  cancer  was 54 ± 12 years.  Cancer 
prevalence was 8.2% and gastric ulcer prevalence was 5.3%. In the same study, the predictive value as 
odds ratio (OR) for dysphagia was 3.1, weight loss 2.6, and 9.5 for those aged above 55 years. All these 
were found to have a positive predictive value for risk of cancer.48
                      A meta-analysis which included 17 case studies and nine cohort studies showed that the 
pooled sensitivities of individual alarm symptoms varied from 9 to 41%, the pooled positive predictive 
value ranged from 4.6 to 7.9%, and was 5.9% for ‘having any alarm symptom’.The pooled negative 
predictive value was 99.4% for‘having any alarm symptom’. The analysis concluded that the risk of 
upper  gastrointestinal  malignancy  in  any  individual  without  alarm  symptoms  is  very  low,  but 
approximately one in four patients with upper gastrointestinal cancer have no alarm symptoms at the 
time of diagnosis.49
                      A recent Meta-analysis 6 states that alarm features have limited predictive value for an 
underlying malignancy.The analysis which 15 studies evaluated a total of 57,363 patients, of whom 
458 (0.8%) had cancer. The sensitivity of alarm symptoms varied from 0% to 83% with considerable 
heterogeneity between studies. The specificity also varied significantly from 40% to 98%. A clinical 
diagnosis  made by a physician was very specific (range,  97%–98%) but not very sensitive (range, 
11%–53%).
                
                   Sundar et al50 in his retrospective study analysed 228 upper GI cancers and found only 14 
patients (6.2%) presented without alarm symptoms. Among those with alarm features 10.9% were 55 
years or younger and 0.9% were aged less than 
45 years.8%of the  patients with cancer  under the age of 55 presented with uncomplicated dyspepsia. 
In patients older than 55 years, 4.4% presented with uncomplicated dyspepsia. The study identified that 
only a very small proportion of patients with uncomplicated dyspepsia had upper GI cancer diagnosed 
at a curative stage.However, limiting open access endoscopy to those with alarm symptoms would have 
potentially ‘‘missed’’ 14 patients, seven of whom had no evidence of metastases on imaging.
                  Numans et al51 suggested thorough evaluation of 'classical' alarm symptoms in dyspeptic 
patients whichmight help minimize unnecessary gastroscopy requests by GPs. In this multicenter study, 
861 consecutive  patients  were investigated  with first-time gastroscopy (study population).  Another 
1153 patients were studied during the next 6 years (validation population). Positive answers regarding 
the symptoms, weight loss and dysphagia, together with negative answers on pain during the night and 
heartburn, predicted malignancy in the study population with an AUC (area under the curve) of 0.90. 
'Alarm symptoms' performed less well in the study population (AUC 0.85), although reproducibility 
was better in the validation population (0.71 versus 0.63).
                       D. J. Bowreyet al52 reviewed a prospectively compiled database of 4,018 subjects who 
underwent open access gastroscopy. Gastroscopy identified esophagogastric carcinoma in 123 (3%) of 
the 4,018 subjects. 
Of these 123 patients, 104 (85%) with esophagogastric cancer had ‘‘alarm’’ symptoms (anemia, mass, 
dysphagia, weightloss, vomiting).The symptoms of the  remaining 15% were those of uncomplicated 
‘‘benign’’ dyspepsia. The patients with ‘‘alarm’’ symptoms had a significantly more advanced tumor 
stage (metastatic disease in 47% vs 11%; p < 0.001), were less likely to undergo surgical resection 
(50% vs 95%; p<0.001), and had a poorer survival (median, 11 vs 39 months; p = 0.01) than their 
counterparts  without  such symptoms.The author concluded that patients  with early curable  cancers 
often  have  only  dyspeptic  symptoms,  and  their  diagnosis  will  be  delayed  until  the  symptoms  of 
advanced cancer develop.
                      M B Wallace et al53 have found that age and the presence of “high risk” symptoms are 
poor predictors of the presence of major endoscopic findings in the upper gastrointestinal tract. Among 
patients aged more than 45 or those with significant predictors,23% had a major pathological finding 
(positive predictive value). Among younger patients with no significant predictors, 88% had no major 
pathological findings (negative predictive value). For cancer alone, 3% of patients with any significant 
predictor (age >45, male sex, anaemia, bleeding) were found to have cancer (positive predictive value), 
and 99%  of patients with no significant predictors had no cancer (negative predictive value).the study 
demonstrate the need for better clinical predictors of upper gastrointestinal pathology. In the absence of 
better clinical predictors, the study also demonstrates the need for less invasive and thus more widely 
applicable endoscopy.
                          A prospective database study of  5224 consecutive patients with uncomplicated  
dyspepsia showed 22 malignancy at endoscopy.These patients were about 20 years older than patients 
with no malignancy (p< 0.001).The Mean age of females with cancer was almost 10 years higher 
compared to  males(p=0.002).The age cut-offs  identified were 35 years for males  and 56 years for 
females.54
                        A long history of symptoms in patients should make cancer unlikely but a symptom 
duration threshold has not been defined in the literature. Use of antisecretory therapy can mask a cancer 
at endoscopy but does not appear to alter the outcome . 
                        The patient who presents with new onset dyspepsia or because of chronic symptoms 
needs an appropriate, evidence based clinical evaluation. The physician generally wishes to ascertain 
the  likely cause  of  the symptoms and exclude  underlying  serious  structural  disease.  However,  the 
patient may actually be presenting not necessarily because of the symptoms per se but because of a fear 
of  serious disease or  recent  psychological  distress.  It  is  reasonable that  the physician identify and 
address such issues as fear of cancer or underlying heart disease in order to optimize management.
                            The patient requiring major reassurance needs to be differently managed than one 
who does not have such concerns, but fear of serious disease probably explains only some health care 
seeking behavior. The physician also needs to decide whether pharmacological therapy is required, 
including which drug and for how long. This in turn depends on the underlying provisional diagnosis, 
which may need to be refined after the patient has initially had a trial of therapy.
MANAGEMENT OPTIONS IN YOUNGER PATIENTS WITH NO ALARM FEATURES
                                A number of management options are available to the clinician in younger patients  
with no alarm features with uninvestigated dyspepsia. A wait-and-see strategy of patient reassurance 
and education, with use of over-the-counter antacids, H2-blockers, or PPIs and reevaluation can be 
considered, particularly in primary care.
                            Another strategy worth considering is prescription of empirical full-dose or highdose 
antisecretory therapy, reserving further evaluation for those who are either unresponsive or have an 
early symptomatic relapse after ceasing medication. Empiric antisecretory therapy was the backbone of 
the guideline proposed by the American College of Physicians and is still widely applied in practice . 
                            A third approach applies H. pylori test and-treat as the initial strategy, currently most 
widely recommended around the world.55,56 Here, young patients without alarm features are tested for 
H. pylori  infection. If  H. pylori  is detected, empiric antibiotic therapy is prescribed in an attempt to 
eradicate  the  infection;  H.  pylori-negative  patients  are  treated  with  empiric  antisecretory  therapy 
initially.A  modification  of  the  H.  pylori  test-and-treat  strategy  is  to  either  prescribe  empiric 
antisecretory therapy first and reserve H. pylori testing later for failures, or apply empiric antisecretory 
therapy after  H. pylori  eradication fails to relieve symptoms. A final approach is to perform prompt 
EGD for all patients with dyspepsia. The best option remains under debate, but new data are available 
to help guide a rational decision.
TEST-AND-TREAT H. pylori
                            The rationale for noninvasive H. pylori testing is the identification of underlying 
peptic ulcer disease. For example, in Scotland where the incidence of peptic ulcer is high, McColl et al.  
showed that in patients with dyspepsia and a positive C13 urea breath test had a duodenal ulcer (DU) in 
40% and gastric ulcer (GU) in 13%; those who were breath test negative had a DU in 2%andGU in 
3%.57 
                             Other studies suggest that between 20% and 60% of patients with dyspepsia who are  
H. pylori infected will have underlying peptic ulcer disease,but this varies widely depending upon the 
background incidence of peptic ulcer.
                            Cost-effectiveness studies in the United States suggest that when the prevalence of H. 
pylori  infection in patients with functional dyspepsia is less than 12% or when the prevalence of  H. 
pylori infection in patients with peptic ulcer disease is less than 48%, initial empirical treatment with a 
PPI is preferable58. 
                             Others have suggested that when H. pylori infection decreases below 20%, empiric 
PPI therapy starts to dominate test-and-treat in uninvestigated dyspepsia.59
ACG 2005:11 
The application of a test-and-treat strategy for H. pylori should be based on the practice setting.  
High  prevalence  populations  in  the  United  States  (e.g.,  recent  immigrants  from  developing  
countries) should undergo test-and-treat as the preferable nonendoscopic strategy. Conversely, in  
communities where gastric or esophagealcancer has a high incidence, prompt endoscopy should be 
considered early but this would not apply to most of the country. 
In low-prevalence populations (e.g., high socioeconomic areas, where the background prevalence of  
ulcer  or  H.  pylori  infection  is  low),  an  alternative  strategy  is  to  prescribe  first  a  course  of  
antisecretory therapy empirically for 4–8 wk. If the patient fails to respond or relapses rapidly on 
stopping antisecretory therapy, then the test-and-treat strategy is best applied before consideration of 
referral for EGD. EGD is not mandatory in those who remain symptomatic as the yield is low; the  
decision to endoscope or not must be based on clinical judgement.
Grade of evidence for test-and-treat or acid suppression:A
Grade of evidence for a H. pylori prevalence of less than 10% in the local community as the cutoff  
for deciding to use empiric acid suppression rather than test-and-treat: C
Disadvantages of Test-and-Treat
                          A notable disadvantage of test-and-treat is that cure of H. pylori infection will only 
lead to a minority reporting symptom improvement, as demonstrated in the above management trials, 
and this can be confusing to the clinician.
                          However,  endoscopy and targeted medical therapy does no better.Indeed, eradication 
of H. pylori infection does not relieve symptoms in all patients with peptic ulcer disease, with at least 
one third continuing to be symptomatic.60,61The choice of the H. pylori test is critical. Many serological 
tests have not been locally validated, and have suboptimal sensitivity and specificity in practice.62 The 
urea breath test and stool antigen test are currently the most accurate noninvasive diagnostic tools and 
can be used with confidence. 
The value of noninvasive H. pylori testing, even if a local evaluated test is applied, still depends on the 
positive and negative predictive value, which in turn is related to the background prevalence of  H. 
pylori infection. When H. pylori is very uncommon, a positive test is more likely to be a false positive. 
Where  H. pylori  infection is highly prevalent,a negative result is more likely to be a false negative . 
Cost-effectiveness studies suggest that the stool test and the urea breath test that detect active infection 
are preferable to serological tests in the United States.63,64 
                         The current treatment of choice for H. pylori infected patients is a combination of PPI 
(standard dose twice daily) with amoxicillin (1 g twice daily) and clarithromycin (500mg twice daily) 
administered for 7–10 days (7-day therapy is approved with rabeprazole; 10-day therapy is approved 
with lansoprazole, omeprazole, pantoprazole, and esomeprazole). Metronidazole (400 mg twice daily) 
may be substituted for amoxicillin in this regimen if the patient is allergicto penicillin. An alternative 
strategy is the combination of Bismuth, metronidazole, and tetracycline (Bismuth subsalicylate 
[Pepto Bismol_] 525 mg QID + metronidazole 250mg QID + tetracycline 500 mg QID) combined with 
a PPI for 14 days .A final issue relates to potential complications of therapy.Antibiotic allergies and 
super-infection can occur. 
                        It is controversial whether eradication of H. pylori infection increases the risk of 
development of reflux esophagitis or reflux symptoms. However, it appears likely that this risk is only 
present in those with a predisposition to GERD who also have severe gastritis in the body or fundus 
that impairs acid secretion, which is reversed with H. pylori eradication; this is likely to be uncommon 
in most of the United States. Hence, this issue while much discussed should not be a major clinical 
concern when contemplating test-and-treat, unless convincing data to the contrary arise. Progression of 
H. pylori gastritis may occur on acid suppression, and some have suggested H. pylori eradication 
should be considered for all patients requiring long-term acid suppression, which seems reasonable.65,66 
An unresolved issue is whether test-and-treat will widen the problem of community acquired antibiotic 
resistance.
PROMPT ENDOSCOPY
Advantages of Prompt Endoscopy
                           There is empiric evidence from a management trial of prompt endoscopy in older  
patients that this is the strategy of first choice. Delaney  et al.  evaluated the cost-effectiveness of an 
initial  endoscopy compared with usual management  in patients  with dyspepsia  over the age of 50 
presenting in primary care.67 A total of 422 patients were randomly assigned to either usual care or 
initial endoscopy; the initial endoscopy arm showed significant improvement in symptom scores and 
quality of life as well as a 48% reduction in the use of PPIs. Hence, initial endoscopy in older patients 
with dyspepsia at least in thisU.K. studywas potentially cost-effective provided the cost of EGDwas 
low. The cost effectiveness of endoscopy in older people in the U.S. setting needs investigation.
                                There is only limited and unconvincing evidence that endoscopy leads to improved  
patient satisfaction scores in dyspepsia. Bytzer el al.  conducted a randomized trial comparing prompt 
endoscopy with empiric H2-receptive blocker therapy in dyspepsia.68 They found there was significant 
improvement in satisfaction scores at one month after endoscopy compared to the empiric antisecretory 
therapy  arm.  In  addition,  66%  of  the  patients  in  the  empiric  therapy  arm  eventually  underwent 
endoscopy during the 12 months of follow-up. However, this unblinded study may have been biased by 
patient and physician expectation that endoscopy is the preferred management strategy, and H. pylori  
status was not considered. 
                            Other studies have suggested that patients with dyspepsia are reassured by EGD and 
may require fewer prescriptions, although the duration of reassurance is not established.69-71 
                            Dyspeptic patients who seek medical attention are more concerned about the possible 
seriousness of their symptoms and are more likely to be concerned about underlying cancer.Health 
anxiety has been shown to lead to a cycle of repeated medical consultations. In a study of primary care 
patients  undergoing  open-access  endoscopy,  Hungin  et  al. demonstrated  that  consultations  for 
dyspepsia  fell  by  57%  in  patients  with  normal  endoscopy  and  by  37%  in  patients  with  minor 
abnormalities at endoscopy. In 60% of patients with normal endoscopy, medication use was terminated 
or  decreased.72 Quadri  and  Vakil  demonstrated  that  one  third  of  patients  referred  for  open-access 
endoscopy for dyspepsia in the United States had high levels of health related anxiety; following a 
normal endoscopy or the demonstration of minor abnormalities, and reassurance by the endoscopist, 
scales for preoccupation with health and fear of illness and death showed significant improvement after 
endoscopy, and the effects were preserved for 6 months.73
Disadvantages of Endoscopy
There are several potential disadvantages of prompt endoscopy for all dyspeptic patients that need to be 
carefully  considered.  Endoscopy is  invasive  and although  the  risks  of  this  procedure  in  relatively 
healthy patients are very low, the issue of the risk-benefit ratio needs careful weighing, particularly as 
the procedure is very unlikely to identify an unexpected structural cause in a young patient with no 
alarm features. Finding esophagitis,  the most likely structural abnormality, may often not lead to a 
change  in  management.74,75 Moreover,  the  high  prevalence  of  dyspepsia  means  that  a  general 
recommendation to perform endoscopies on all patients would be very costly and would overwhelm 
endoscopy services.  Furthermore,  it  is  contentious  that  prompt  EGD provides  any direct  benefits 
despite some positive studies quoted above. One study evaluated management strategies in 326 primary 
care patients with dyspepsia; endoscopy was not superior to any of the empirical treatment strategies 
utilized in this study.76 
A systematic review concluded that most data failed to support the view that endoscopy alone improves 
patient outcome in dyspepsia compared with other
empiric strategies.77
EMPIRIC ANTISECRETORY THERAPY IN UNINVESTIGATED DYSPEPSIA
The  American  College  of  Physicians  in  1985  recommended  an  empiric  trial  of  an  H2  receptor 
antagonist for 6–8 wk; those who relapsed after therapy or those who failed
to respond to therapy in 7–10 days were to be referred for endoscopy.
The widespread availability of PPIs has resulted in this class of agents frequently being prescribed as 
initial empiric therapy in uninvestigated dyspepsia in place of H2 receptor antagonists.78
A meta-analysis of several large studies has demonstrated a short course of PPI therapy compared with 
a H2-receptor antagonist, alginate, or placebo in primary care provides better symptomatic outcomes.79 
However,  these  studies  frequently  included  patients  with  symptomatic  reflux  disease  and  did  not 
exclude peptic ulcer. 
It is unknown whether GERD or ulcer disease, or both, accounts for the apparent short-term benefits of 
empiric therapy in these reports.
There are limited data that prokinetic therapy employed as an empiric strategy may be efficacious in 
uninvestigated dyspepsia. Kearney  et al.  noted no significant difference in the severity of dyspeptic 
symptoms among 60 patients randomized to receive cisapride as compared to placebo in the setting of 
uninvestigated dyspepsia and negative H. pylori-serology.80 
Quartero et al. conducted a trial in primary care of 563 patients who were randomized to ranitidine or 
cisapride; treatment success was similar in both groups but was under 50%, and the relapse-free periods 
were also similar with both drugs.81 
A randomized trial in H. pylori-negative dyspepsia from Canada demonstrated that cisapride had low 
efficacy and was inferior to acid suppression.82 Moreover, cisapride is no longer available because of 
rare toxicity from QTC prolongation and sudden death. There have been no trials of metoclopramide, 
tegaserod or domperidone in the management of uninvestigated dyspepsia. 
Obvious disadvantages of empiric antisecretory therapy include the concern that peptic ulcer disease 
will  be  inappropriately  and  inadequately  treated,  and  patients  subsequently  may  present  with 
complicated ulcer disease if for any reason the therapy is ceased. 
Antisecretory therapy can also lead to misdiagnosis of peptic ulcer disease at subsequent endoscopy, as 
the  ulcer  will  more  likely heal  and  be  missed.  The  impact  of  acid  rebound in  dyspepsia  remains 
unclear. Empiric antisecretory therapy may lead to long-term inappropriate maintenance therapy that 
the patient does not require. 
It  is  unclear  whether  antisecretory therapy postpones  eventual  investigation  or  not,  which  in  turn 
impacts on its potential cost-effectiveness.
H.pylori TEST-AND-TREAT VERSUS EMPIRIC ANTISECRETORY THERAPY
There are only very limited data comparing empiric H. pylori treatment versus empiric PPI therapy. 
Manes et al83 compared test-and-treat with PPI therapy for a month with 12 months of follow-up in a 
secondary care setting in Italy. In the test-and-treat arm, 56% were eventually endoscoped because of 
poor symptom control, but none had a peptic ulcer; in the PPI arm, 88% were endoscoped and 17% had 
a peptic ulcer, but most (88%) were infected with H. pylori. 
More studies are needed, but these data suggest that in  H. pylori  positive dyspeptic patients, empiric 
PPI therapy is not the management option of choice in areas where the prevalence of H. pylori is high
ACG 200511 :
In H. pylori-negative cases with uninvestigated dyspepsia and no alarm features, an empiric trial of  
acid suppression for 4–8 wk is recommended first-line therapy (Grade of evidence: A)
If initial acid suppression fails after 2–4 wk, it is reasonable to step up therapy, although this is  
based on expert opinion only; this may require changing drug class or dosing. In the absence of  
established  prokinetic  drugs  for  dyspepsia  in  the  United  States,  this  drug  class  is  not  
currentlyrecommended as first-line therapy for dyspepsia inthe United States.(Grade of evidence: C)
In patients who do respond to initial therapy, it is recommended that treatment be stopped after 4–8  
wk and if symptoms recur, another course of the same treatment is justified.There are no data on  
long-term self-directed therapy in this condition, although this may be worth considering in some  
patients.(Grade of evidence: C)
MANAGEMENT OF DOCUMENTED FUNCTIONAL DYSPEPSIA
                            Once a diagnosis of functional dyspepsia is confirmed by a negative endoscopy, an  
empiric trial of therapy is commonly prescribed. However, the benefits of all therapies in this condition 
have been questioned.  Many patients  do not  require  medication for  dyspepsia  after  they have had 
reassurance and education.  It  is  therefore important  for  the clinician to  explain the meaning ofthe 
symptoms and their benign nature. 
                               Ascertaining why a patient with long-standing symptoms has presented on this 
occasion for care can be helpful, as this may identify those who have fears of an underlying serious 
disease  or  specific  psychological  distress  that  can  be  addressed.  Potential  precipitating  factors  in 
dyspepsia remain poorly defined. High-fat meals should be avoided; eating frequent and smaller meals 
throughout the day can sometimes be helpful. Specific foods that precipitate symptoms can be avoided. 
Food intolerance is uncommon, however, and food allergy very rare. Follow-up of the patient helps 
determine the natural history and allows further correction of faulty ideas and provides reassurance that 
can be very helpful in long-term management.
                         Antacids and sucralfate were not superior to placebo in functional dyspepsia based on a  
Cochrane review.78 However,a recent trial  of simethicone has suggested potential benefit  compared 
with placebo, and in another study equivalence with cisapride.84
                        A Cochrane review of 8 trials of H2 receptor antagonists with 1,125 patients showed a 
relative risk reduction of 30% but the quality of the trials was generally poor . PPIs in this review also 
produced a relative risk reduction of approximately 30% and the quality of the trials was better.78
                      An economic model suggested that PPI therapy was cost-effective for functional  
dyspepsia in the United States.85 However, in a recent randomized trial of 453 patients from Hong 
Kong, the proportion of patients achieving complete relief of dyspepsia with lansoprazole 30 and 60 
mg was 23% and 23%, respectively, compared with 30% on placebo.86
                      In contrast, another recent trial reported significant benefit with lansoprazole in a U.S. 
population.87 H. pylori status is unlikely to affect the therapeutic outcome of acid suppression therapy 
in functional dyspepsia. Large trials have failed to identify any difference in therapeutic outcome in H. 
pylori-positive  versus  negative patients, although Blum et al.  did identify a superior response to PPI 
therapy in H. pylori-positive patients.88
                      Eradication of H. pylori in functional dyspepsia is controversial. Two high-quality meta-
analyses  have reached different conclusions but this  may be likely explained by which trials  were 
included and excluded in each systematic review. Updating these meta-analyses now suggests  that 
when all appropriate trials are considered, there is a small but significant therapeutic gain achieved with 
H. pylori eradication in functional dyspepsia, with the number needed to treat being 15. While longer 
than 1-yr follow-up data are generally lacking, one 5-yr study suggests any benefit will persist . 
                       On the basis of the evidence, it is acceptable to offer H. pylori eradication therapy to 
infected patients with functional dyspepsia. The results also imply that offering H. pylori  eradication 
therapy empirically to those with otherwise uninvestigated dyspepsia who are infected is reasonable 
even if ulcer disease is unlikely. Moreover, H. pylori eradication in those with documented functional 
dyspepsia may help prevent ulcer disease, although convincing evidence is not available. 
                       Hsu et al. observed during 1yr of follow-up in a randomized controlled trial comprising 
161 patients with functional dyspepsia, 2 patients in the H. pylori eradication treatment group (3%) and 
6 patients in the placebo group (8%) developed peptic ulcers at repeat endoscopy .
                      The benefit of other treatments remains uncertain. A Cochrane review included 12 trials  
with prokinetics comprising 829 patients and showed that there was a relative risk reduction of 50%, 
compared with placebo, but most of the studies were with cisapride . Moreover, analysis of the studies 
suggested that  publication bias at  least  partly explains  the apparent  benefits  of prokinetic  therapy. 
Prokinetics should be reserved for difficult cases as options in the United States are few and current 
agents (e.g., metoclopramide, erythromycin, tegaserod) have limited or poorly established efficacy,or 
side-effects are common . 
                        Routine use of gastric emptying studies is not recommended as improvements in gastric  
emptying do not correlate well with symptom improvement . Drugs that relax the gastric fundus (e.g., 
tegaserod,  cisapride,  sumatriptan,  buspirone,  clonidine,  some  SSRIs,  nitric  oxide  donors)  may 
theoretically improve some dysmotility-like dyspepsia (e.g.,  early satiety) but adequate randomized 
controlled trials are lacking . 
                        Antidepressants are also of uncertain efficacy in functional dyspepsia but are often 
prescribed. There are insufficient data on the use of tricyclic antidepressants such as amitryptyline in 
dyspepsia,  but  small  studies  have  suggested  benefit;  however,the  beneficial  effect  of  low-dose 
amitryptyline seen in functional dyspepsia was not related to changes in perception of gastric distension 
. An increased tolerance to aversive visceral sensations may play a role in the therapeutic effect. There 
are limited data with the SSRIs. Psychological therapies are promising, particularly hypnotherapy, but 
more data are needed in larger patient populations before these can be recommended for routine use. 
Other alternative therapies such as herbal preparations remain of unproven value .
ACG 2005 :
The management of endoscopy-proven functional dyspepsia is particularly challenging when initial  
antisecretory therapy and H. pylori eradication fails. Patients who fail to respond to simple measures  
need to have their diagnosis reconsidered. Dietary therapy has no established efficacy but may help 
some individuals. There are very limited data to support the use of herbal preparations, simethicone,  
and  low-dose  tricyclic  antidepressants  in  functional  dyspepsia.  Bismuth,  sucralfate,  and 
antispasmodics  are  not  established  to  be  of  benefit  over  placebo  in  functional  dyspepsia.  
Hypnotherapy, psychotherapy, and cognitive-behavioral therapy are supported by limited studies but  
cannot be generally recommended at the present time.
Grades of evidence:
Dietary modification: C
Simethicone: B
ADDITIONAL DIAGNOSES AND TESTING IN REFRACTORY CASES
                              Abdominal wall pain can be confused with functional dyspepsia; physical  
examination here is diagnostic (increased rather than reduced tenderness on tensing the abdominal wall 
muscles). Biliary pain is characteristic and different from dyspepsia; ultrasound usually is unhelpful in 
the absence of typical biliary pain.                           Exclusion of atypical GERD with esophageal pH 
testing may alter management; at least 20% of patients with diagnosed functional dyspepsia clinically 
turn out to have GERD on esophageal pH studies . Thus, even if a trial of PPI therapy has failed, pH 
testing may be considered off  therapy,  although the  yield in  this  particular  setting is  not  defined. 
Abdominal  imaging  to  rule  out  chronic  pancreatitis  or  small  bowel  pathology  may  be  worth 
considering too but usually has a low yield; capsule endoscopy does not yet have an established role 
here. Gastric function testing (gastric emptying; gastric accommodation; response to a nutrient or water 
load)  may not  change management  even if  abnormalities are  detected,  although,  if  there  is  gastric 
dysaccomodation, trials of various drugs to relax the fundus may be worth trying empirically . 
                             Questions about symptoms consistent with IBS may lead to a change in the 
diagnosis.  Colonic  evaluation may be considered  even if  there  are  no bowel  disturbances  because 
disease in the transverse colon or elsewhere can occasionally present with referred symptoms labeled 
dyspepsia. 
                            A drug history is helpful but aside from NSAIDs, drugs are rarely major contributors 
to  chronic  dyspepsia  according to the available  evidence .  Diabetic  radiculopathy can cause upper 
abdominal pain and EMG is diagnostic. Evaluation for referred pain from the chest or back should be 
considered in difficult cases. 
                                 Finally, consider looking for rare metabolic or other causes of upper abdominal 
pain  including  thyroid  disease,  electrolyte  abnormalities,  hypercalcemia,  heavy  metals,  acute 
intermittent porphyria, angioneurotic edema, familial mediterranean fever, chronic intestinal angina, 
superior  mesenteric  artery  syndrome,  liver  disease  (hepatoma,  steatohepatitis),  eosinophilic 
gastroenteritis, or connective tissue disease.
                   
Algorithm for the management of Univestigated dyspepsia
                                                                     
MATERIALS AND METHODS
All  patients  who  attended  the  Gastroenterology  Outpatient  clinic  of  the  Stanley  Medical  College 
Hospital  between  October  2008  and  March  2009  with  features  of  dyspepsia  were  enrolled.Those 
patients with alarm features were included in the study.
Alarm  features  defined  in  the   study  were  dysphagia,persistent  vomiting,early  satiety, 
anemia,anorexia,unintended  weight  loss,Upper  Gastrointestinal  bleed,,abdominal  mass, 
lymphadenopathy, jaundice, High risk features(family history of GI cancer,previous history of gastric 
surgery). Those dyspeptic patients above 45 years of agewithout alarm features were also included for 
endoscopic  evaluation  as  per  the  recommendation.  Patients  with  prior  NSAID  use,known 
diabetics,medical comorbidities,known gastric/esophageal cancer were excluded.
At their first visit,data was collected in a structured proforma (Annexure I) incorporating the upper 
abdominal symptom questionnaire and were given a full diagnostic workup,as considered appropriate 
based on the presenting symptoms.
The  data  included  age,  gender,  educational  status,  income,  family members,  dyspeptic  symptoms, 
alarm  symptoms  with  their  duration,relevant  findings  on  physical 
examination,basiclaboratorydata(Hemogram,Bloodsugar,Bloodurea,Serumcreatinine),Imaging(X  ray 
chest,Ultrasound abdomen,CT abdomen)  and findings  at   UGI  endoscopy.Questionnaire  data  were 
collected  prospectively  in  the  above  mentioned  time  period.  Data  were  then  retrospectively 
analysed.Ethics committee approval was obtained prior to initiaton of the study
STATISTICAL ANALYSIS
Prevalence estimates were done for all alarm features,age and gender related factors,without ,alarm 
features,enodoscopy outcomes.Univariate analysis were assessed using Pearson’s χ2  test; some factors 
done  with  chi  square  test(Fisher’s  exact  probability  test).Comparisons  were  performed  between 
positive endoscopy outcomes with all independent variables.
Multivariate analysis was done with multiple linear logistic regression model.Significant alarm features 
which were identified with univariate analysis  were entered into a regression model and backward 
stepwise  elimination  was  used  to  identify  the  best  subset  of   factors  that  predicted  the  positive 
endoscopy outcome.i.e gastro esophageal malignancy.Odds ratio with 95% confidence intervals were 
recorded for all significant factors identified in univariate and multivariate analysis.P value of < 0.05 
was considered significant. 
                                             
RESULTS
A total of 1984 patients with symptoms of dyspepsia  presented to the Gastroenterology Outpatient 
service during the study period. 283 patients satisfied the inclusion criteria and were enrolled in the 
study.
2 patients did not turn up for the   Upper Gastrointestinal Endoscopy procedure.
2 patients had incomplete study as they were not cooperative during the endoscopy procedure.
In total,279 patients who underwent endoscopy successfully entered the study.
There were 162(58.1%) males and 117 (41.9%) females.
Mean patient age was 50.73+ 13.88 and no gender difference observed        
(Males Vs Females = 51.06 + 14.24 Vs 50.27 + 13.43,p=0.64).
205 patients (73.5%) were above 45 years of Age.
Fig 1. Gender prevalence
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Anorexia,weight loss,anemia were the common alarm features noted overall.In the younger age group 
i.e < 45 years ,the common alarm features were weight loss(11.8%) and anemia(11.8%).Whereas in 
age>45years, anemia was the commonest(44.8%). Combination of alarm features present in 65.2% of 
patients.Anemia was more prevalent in both gender.
Fig 2. Prevalence of individual alarm features in relation to age group
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(1-dysphagia,2-persistent vomiting,3-early satiety,4-Upper GI bleed,5-anorexia, 6-wt loss,
7-easy fatiguability,8-anemia,9-mass abdomen,10-high risk features, 11-alarm combination)
Fig 3. Prevalence of alarm features – gender related
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Prevalence of alarm features in relation to Age ,Gender:
                     
                  Table 1.Gender Vs Alarm
Alarm present Alarm absent
Males 145 17
females 97 20
Total 242 37
 
                    Table 2. Age group Vs Alarm
Alarm present Alarm absent
Age > 45 years 168 36
Age < 45 years 75 0
Total 243 36
          Table 3. Gender Vs Alarm in Age > 45 years
Alarm present Alarm absent
Males 101 17
Females 67 19
Total 168 36
                                                   
There was no significant difference in the prevalence of alarm features with respect to Gender overall.
Alarm features were more prevalent in older age groups(age > 45 years) compared to younger age 
group(statistically significant p<0.001).
In the age group > 45 years , there was no significant difference in the prevalence of alarm with respect 
to gender.
              
(p = 0.1)
(p< 0.001)
(p = 0.2)
  Table 4. Gender Vs alarm combination
Alarm combination 
present
Alarm combination 
absent
Males 112 50
Females 70 47
Total 182 97
No significant difference in gender noted with respect to prevalence of alarm combination.
Malignancy outcomes :
Of the 279 patients who underwent endoscopy,38 patients(13.6%) were diagnosed to have malignancy 
(proven histologically).17 presented with esophageal malignancy,       18 with gastric malignancy, 2 
with GE Junction malignancy and 1 patient with periampullary malignancy.
Benign lesions were found in 160 patients(57.3%): DU (15.6%), gastric ulcer (GU) (7.1%), gastric 
erosions(9.1%),oesophagitis (6.8%), gastritis (10.2%) and duodenitis (13.6%).Normal study found in 
81 patients(29.1%).
             
                      Table.5 Age distribution of Upper GI malignancies
Total number 
of patients
< 45 years 45 – 60 
years
> 60 
years
Total number of pts with 
upper GI malignancies
38 4(10.5%) 19(50%) 15(39.5%)
Pts with alarm features 37(97.4%) 4(10.5%) 18(47.4%) 15(39.5%)
Pts without alarm features 1(2.6%) 0 1(2.6%) 0
                           About 89.5% of patients with Upper GI malignancy was found in the                       age 
(p = 0.1)
group > 45 years. 86.9% of these patients presented with alarm.Only 1 patient (2.6%) presented 
without alarm. 
                          In the younger age group all patients (100%) presented with alarm.
                Table.6 Gender distribution of Upper GI malignancies
Total number 
of patients
Males Females
Total number of pts with upper 
GI malignancies
38 25(65.8%) 13(34.2%)
Pts with alarm features 37(97.4%) 25(65.8%) 12(31.6%)
Pts without alarm features 1(2.6%) 0 1(2.6%)
65.8% of males with Upper GI malignancy presented with alarm whereas 31.6% of females presented 
with alarm. 
       TableNo7.Age group with alarm Vs malignancy
Malignancy 
positive
Malignancy 
negative
Age > 45 yrs 33 135
Age< 45 yrs 4 70
Total 37 205
Prevalence of malignancy was significantly associated with older age group patients (>45 years) with 
alarm features(p=0.008) compared to younger age group with alarm.
Table 8. Gender Vs malignancy outcome among patients > 45 years
Malignancy 
positive
Malignancy 
negative
Males 22 79
(p = 0.008)
Females 11 56
Total 33 135
Among the patients of above 45 years,there was no significant difference between males and females in 
relation to malignant outcomes.
Table 9. Significance of individual alarm features & alarm combination in the   diagnosis of 
Upper GI malignancy 
S.No Variables Malignancy 
positive
Malignancy 
negative
P value Odds 
Ratio(95%CI)
1. Age >45 yrs 34 170
<45 yrs 4 71
0.01 3.55(1.21-10.37)
2. Sex Males 25 137
Females 13 104
0.3 -
3. Dysphagia Yes 16 32 <0.0001 4.75(2.25-9.99)
No 22 209
4. Vomiting Yes 13 35
No 25 206
<0.003 3.06(1.43-6.54)
5. UGI Bleed Yes 4 32
No 34 209
0.8* -
6. Early satiety Yes 8 11
No 30 230
0.01* 5.57(2.07-14.96)
7. Anorexia Yes 28 113
No 10 128
0.002 3.17(1.47-6.81)
8. Weight loss Yes 31 79
No 7 162
0.0001 9.08(3.83-21.52)
9. Easy 
fatiguability
Yes 12 18
No 26 223
0.0001* 5.71(2.47-13.18)
10. Anemia Yes 36 122
No 2 119
<0.0001 17.55(4.13-74.55)
11. Mass 
abdomen
Yes 3 1
No 35 240
0.008* 20.57(2.08-200.3)
12. High risk 
features
Yes O 8
No 38 233
0.4 -
13. Alarm 
combination
Yes 13 39
No 25 202
0.008 2.69(1.26-5.71)
P=0.43
Statistically  significant  variables  on  Univariate  analysis  were  Age>45  yrs(p=0.01), 
dysphagia(p<0.0001)vomiting(p<0.003),earlysatiety(p=0.01),anorexia(p=0.002),
weightloss(p<0.0001),easyfatiguability(p=0.0001),anemia(p<0.0001),  
mass abdomen(p=0.008) and alarm combination(p<0.001). Alarm features like Upper Gastrointestinal 
bleed,High risk features and gender were not statistically significant to diagnose or to predict Upper GI 
malignancy.
                  
            Table 10. Duration of symptoms and outcome of endoscopy
S.No Alarm 
duration
           Outcome(%)    Χ2 test  P value
Malignancy 
positive
Malignancy 
Negative
32.1 <0.0001(df=3)
1. < 3 months 33 61
2. 4 – 6 months 2 20
3. 7 – 9 months 1 24
4. > 9 months 0 48
The above table shows an inverse correlation of positive outcomes of endoscopy 
i.e  malignancy  positive  with  the  duration  of  alarm  symptoms.This  is  is  statistically 
significant(p<0.0001).
Table.11 Multivariate analysis using multiple linear logistic regression model   
                with   backward  elimination
S.No Variables P value Odds ratio 95%CI
1. Age > 45 years 0.02 4.27 1.18 – 15.3
2. Dysphagia 0.003 4.3 1.6 – 11.7
3. Vomiting 0.02 3.36 1.18 – 9.51
4. Early satiety 0.2 - -
5. anorexia 0.1 - -
6. Weight loss 0.008 6.2 1.6 – 24.4
7. Easy fatiguability 0.13 - -
8. Anemia 0.01 9.1 1.6 – 50.5
9. Mass abdomen 0.6 - -
10. Alarm combination 0.3 - -
The 10 variables which showed significant values bu Univariate analysis were entered in multivariate 
analysis.5 of the 10 variables emerged statistically significant after multivariate analysis using Multiple 
linear logistic regression model.
They were Age > 45 years(p=0.02), Dysphagia(p=0.003), Vomiting(p=0.02),
Weight loss(p=0.008) and Anemia (p=0.01).
DISCUSSION
It  is well recognised that clinical  history is a poor guide to the underlying diagnosis of dyspepsia. 
Approximately  3–4%  of  the  population  consult  their  general  practitioner  with  Upper  intestinal 
symptoms each year, of which over 10% will have so-called alarm symptoms.It is important to identify 
the malignancy in patients presenting with dyspepsia.The set guidelines by the Western world may help 
in picking up the lesion. Unfortunately malignancies were picked up late in their presentation by the 
alarm symptoms and no standard guidelines established for the Indian population.
Also not all the alarm features mandate an immediate endoscopy.Eventhough the cost of endoscopy is 
low in India compared to Western world,it may result in overburden of the working staff,wasting of 
manpowerand resources.
The present study highlighted that dysphagia, age>45years, persistent vomiting, anemia and weight 
loss  were  the  alarm  features  in  dyspeptic  patients  which  predicted  significantly  the  malignant 
outcomes.  Kapoor et  al48 in  his  study identified  dysphagia (odds ratio  (OR) 3.1 (95% confidence 
interval  (CI)  1.80–5.22)),  weight  loss  (OR 2.6  (95% CI  1.53–4.41))and  age  >55  years  to  be  the 
significant positive predictive factors for cancer.This is similar to the present study except for the age 
group and alarm features like anemia,vomiting.
Age is an important criterion (even without alarm features) while screening patients with dyspepsia for 
cancer. Among the Western population, the incidence of oesophageal and gastric cancers is very low 
for patients below the age of 45 years, and the Western recommendations do not justify the use of 
endoscopy in these patients to detect early cancer.The incidence of gastroesophageal cancers in Indian 
population is high and the age of onset ,presentation were early.Sumathi et al45 in her recent study 
highlighted  that  even  taking  the  age  cut-off  as   45  years  for  diagnostic  endoscopy,  18.3%  of 
malignancies  were  missed.The  study  arrived  an  age  cut  –  off  (males  -43.5  years,females  -  38 
years).The present study eventhough taken the age cut-off as 45years(as per ACG 1985 guidelines) , it 
was found to be the single most diagnostic predictor for malignancy.This again signifies that age cut – 
off for the Indian population should be separately assigned by prospective controlled studies in future 
and not to follow the age age > 55years as an alarm feature to proceed with endoscopy(ACG 2005).
The Prevalence of alarm features were more commonly seen in dyspeptic patients in older age group. 
Sundar et a50 in his retrospective study found that alarm features were present more significantly in age 
> 45.The present study also showed a significant difference in the prevalence of alarm features (p< 
0.001) between the younger and older age groups.Also the presence of alarm in older age group was 
significantly associated with positive malignancy outcomes in patients  with dyspepsia.  The present 
study showed that alarm features in age > 45 years predict more significantly(p = 0.008) the malignant 
outcomes than younger age group with alarm. 
The prevalence  rates  of  gastresophageal  cancer  vary.Depending on  them,the  factors  which  predict 
cancer may also vary.Kapoor et al showed a prevalence rate of 3.8% in his study. The present study 
found the prevalence to be 13.6%.
.
.
Summary and Conclusions
The alarm features like dysphagia(p=0.003), persistent vomiting(p=0.02), 
anemia(p=0.01),  age>45 years(p = 0.02)  and weight  loss(p = 0.008)  were  identified  as  significant 
predictors for Gastroesophageal malignancy in dyspeptic patients.
No gender difference observed to influence the malignant outcome(p = 0.3).
The duration of alarm inversely correlates with malignant outcome(p<0.0001).
Presence of alarm combination do not significantly increase the chances of malignancy (p=0.3)
Alarm features in age > 45 years predict more significantly(p=0.008) the malignant outcomes than 
younger age group with alarm.
Alarm features like Upper GI bleed(p=0.8), early satiety(p=0.2), anorexia(p=0.1),
easy  fatiguability(p=0.13),  mass  abdomen(p=0.6)  do  not  predict  significantly  Gastroesophageal 
malignancy. 
Based on the results of the present study,we recommend the following guidelines that can be followed 
in our set up:
1.Irrespective  of  age  group,  any  dyspeptic  patient  with  alarm  should  be  subjected  to  Upper  GI 
endoscopy to rule out malignancy as per the recommendation.But the urgency of endoscopy can be 
prioritised.
 (a)  In Age > 45 years presenting with alarm,Upper GI endoscopy should be done urgently/at  the 
earliest without even waiting for the baseline investigations.
   (b) In Age > 45 years without alarm & younger patients with alarm,Upper GI scopy can be done in an 
elective basis or after undergoing baseline investigations.
2.Patients presenting with dysphagia,vomiting ,weight loss,anemia should be done endoscopy in an 
urgent basisThe above indications may minimize the workload to the endoscopist and at the same time 
identifies the malignancy at the earliest.
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ANNEXURE I
Predictors of positive endoscopic findings in Dyspeptic patients with alarm features
Name :                                                              Age/Sex :                                              MGE No :
   
Occupation :                                                      Education :                                           DOR :
Address :
Marital status :                                                   No of children :                               No of family members :
Net family income :                                           Religion :
Veg/Non veg :
Clinical diagnosis :
S.no Investigations Report 
S.No Clinical parameters Duration/Details S.No Clinical examination Status/details
 1 Dysphagia 1 Anemia
2 Hold up throat 2 Jaundice
3 Odynophagia 3 Clubbing
4 Heart burn 4 Edema
5 Retrosternal  chest pain 5 Lymphadenopathy
6 Regurgitation 6 Oral thrush
7 Epigastric pain 7 Pulse rate
8 Post prandial epigastric fullness 8 BP
9 Epigastric discomfort 9 BMI
10 Abdominal bloating 10 ABDOMEN                 
11 Nausea/vomiting                  Epigastric tenderness
12 Early satiety                  Epigastric mass 
13 Ball rolling movements                  VGP                  
14 Hemetemesis                  Scar 
15 Melena                   Hepatomegaly 
16 Anorexia                  Splenomegaly 
17 Weight loss                   Others
18 Mass abdomen 11 Per rectal
19 Easy fatiguability/exhaustion
20 jaundice
21 Abdominal distension
22 Family history of GI malignancy
23 H/o previous gastric surgery
1 Hb
2 TC
3 DC
4 ESR
5 Platelet count
6 Peripheral smear
7 B.Sugar
8 B.urea./S.Creatinine
9 LFT
10 CXR
11 AXR
 
USG Abdomen :
CECT(thorax/abdomen) :
UGI SCOPY  :
Biopsy report :
.
                
